Experimental drug combo tested for rare, deadly castleman disease
NCT ID NCT00092222
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 8 times
Summary
This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the disease progresses over time. Participants will have extra blood draws and biopsies to help researchers learn more.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Etoposide, interferon-alpha, zidovudine, valganciclovir, bortezomib, rituximab, liposomal doxorubicin
- What this could lead to
- If successful, this study could improve understanding and treatment options for KSHV-MCD, a rare and deadly disease with no standard therapy.
- What could go wrong
- This is a small, early-phase study (75 participants) with multiple experimental drug combinations. Side effects can be severe, and there is no guarantee of direct benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HHV-8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Blood test may foretell Radiation's toll on the gut
- Bringing HIV care to the community: a new test in zambia